Author Affiliation: Duke Clincal Research Institute, Durham, NC.
Published online March 14, 2006 (doi:10.1001/jama.295.13.jed60020).
Antithrombotic therapy has become a major defense against the assault of atherosclerosis on society, and accordingly, “atherothrombosis” has become a commonly accepted term in the cardiovascular practice community. Understandably, exploration of the biology of atherothrombosis has led to the development of a variety of drugs intended to block coagulation and thereby prevent arterial thrombosis. The OASIS (Organization to Assess Strategies for Ischemic Syndromes) 6 trial reported in this issue of JAMA by the OASIS-6 Trial Group1 represents another major milestone in this remarkable saga.
Califf RM. Fondaparinux in ST-Segment Elevation Myocardial InfarctionThe Drug, the Strategy, the Environment, or All of the Above?. JAMA. 2006;295(13):1579-1580. doi:10.1001/jama.295.13.jed60020